Skip to main content
OpenTrials
Completed

NCT Number: NCT05070091

The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.

The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PCR-confirmed COVID-19 infection
  • volunteers consenting to participate

Exclusion criteria

  • no consent

Treatment and study plan

Primary outcomes

  1. Meeting the primary endpoint criteria.

    Time frame: Time of hospitalization, typically less than one month.

    Primary endpoint is defined as a composite endpoint including death, mechanical ventilation, vasopressor use, noninvasive ventilation, prolonged hospital stay (>10 days).

Sponsors and collaborators

Lead sponsor

Medical University of Gdansk

Other

Collaborators

  • National Center for Research and Development, Poland

Registry information

Acronym: ENDO-COVID19

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 6, 2021
Registry last updated
Feb 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.